Lisata Therapeutics, Inc. - Common Stock LSTA 深 滬
交易中 10-28 11:12:30 美东时间
2.71
-0.090
-3.21%
華盛通- 最 高2.77
- 今 開2.73
- 成交量 5.11万股
- 最 低 2.542
- 昨 收 2.80
- 總市值 2372.85万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 1.87
- 委 比 58.73%
- 總股本 875.59万
- 歷史最高 1483.50
- 量 比 5.66
- 振 幅 8.14%
- 歷史最低 1.87
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lisata Therapeutics Highlights Cancer Therapy Innovations
Lisata Therapeutics ( ($LSTA) ) just unveiled an update. On October 14, 2025, L...
10-15 04:37
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics and Catalent have entered a global license agreement to develop certepetide as payloads in Catalent’s SMARTag ADC platform for treating difficult-to-treat diseases. Catalent gains rights to evaluate certepetide and its analogs across multiple ADCs, with Lisata eligible for over $10M in milestones and revenue sharing. The collaboration leverages certepetide’s potential to enhance tumor targeting and treatment outcomes, supporte...
10-08 12:30
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Lisata Therapeutics announced promising preliminary results from its Phase 1/2a CENDIFOX trial combining certepetide with FOLFIRINOX for pancreatic ductal adenocarcinoma (PDAC). Among 35 patients, 10 achieved R0 resection with 50% success and 70% experienced partial tumor response. The two-year overall survival rate was 60%, with a 12-month median disease-free survival. Enhanced immune cell infiltration and increased PD-1, PD-L1 expression indica...
09-29 12:00
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics announced that its CEO, David J. Mazzo, Ph.D., will provide a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. Lisata, a clinical-stage pharmaceutical company, focuses on developing innovative therapies for advanced solid tumors. Its drug candidate, certepetide, a...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.
08-21 19:18
Lisata Therapeutics Reports Strong Q2 2025 Financials
The latest announcement is out from Lisata Therapeutics ( ($LSTA) ). On August ...
08-08 04:43
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics reported a business update and Q2 2025 financial results. The company has a cash runway extending into Q4 2026 with no debt, funding current clinical programs through their next data milestones. Clinical trials include ASCEND, BOLSTER, and CENDIFOX, showing positive preliminary data for certepetide in treating solid tumors. Q2 revenue was $70K, down from Q2 2024 due to no revenue in the prior year. Operating expenses decreased...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics announced it will report its second-quarter 2025 financial results on August 7, 2025, followed by a conference call at 4:30 p.m. ET. Interested parties must register via the provided link to receive dial-in details. The call will also be webcast on the company's website and available for replay for 12 months. Lisata focuses on developing therapies for advanced solid tumors, with its candidate certepetide aiming to improve drug...
07-31 12:00
